Episode 113: Lessons Learned in Alzheimer Drug Development
Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Ian Kremer. [LISTEN TIME: 35 minutes]
Ian Kremer
Episode 113 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 113, "Lessons Learned in Alzheimer Drug Development" features a conversation with Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, who spoke on several relevant topics regarding Alzheimer care as new novel therapeutics emerge. He talked about the lessons learned from the recent discontinuation of aducanumab (Aduhelm; Biogen), and the potential and limitations lecanemab (Leqembi; Eisai) and donanemab (Eli Lilly) may bring. Additionally, he provided comments about what matters to patients, the perception of the FDA approval process, and what is considered "clinically meaningful." Furthermore, he gave perspective on ways to improve drug development and emphasized the need for policy decisions to be based on scientific evidence and not by sensationalized headlines.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Agrees to New Specialized Protocol for Phase 3b Study of ALS Agent NurOwn
- FDA Approves Alternate Administration Routes for Antiseizure Medication Cenobamate
- Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com
EPISODE BREAKDOWN
- 1:10 – Promise in the Alzheimer field in 2024
- 4:05 – Ways of improving efficiencies with drug develpment
- 9:10 – Discontinuation of aducanumab
- 11:10– Neurology News Minute
- 13:50 – Lessons learned from aducanumab, antiamyloid therapies
- 22:10– Conversations between clinicians and patients surrounding expectations/limitations of antiamyloid therapies and available treatments
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
